Yahoo Finance 3 Healthcare Mutual Funds for Steady Returns
Investors often rely on the healthcare sector to safeguard their investments. This is because healthcare services do not see their demand varying too much with respect to market conditions and thus offer sufficient protection to the capital invested. Many pharmaceutical companies also offer regular dividends.
Companies that consistently pay out dividends are financially stable and generate steady cash flows, irrespective of market conditions. Mutual funds are perfect for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight.
Below, we share with you three healthcare mutual funds, viz., Janus Henderson Global Life Sciences Fund JNGLX, Vanguard Health Care Fund VGHCX and T. Rowe Price Health Sciences Fund PRHSX. Each has earned a Zacks Mutual Fund Rank #1 (Strong Buy) and is expected to outperform its peers in the future. Investors can click here to see the complete list of funds.
Janus Henderson Global Life Sciences Fund invests its net assets in securities issued by firms that the portfolio managers believe have a life science emphasis to meet its investment goal. JNGLX has created a fundamental policy mandating a minimum investment of its total assets in securities issued by firms categorized under the "life sciences" sector as part of its strategy to locate such companies.
Janus Henderson Global Life Sciences Fund has a three-year annualized return of 8.6%. As of March 2023, JNGLX held 99 issues, with 6.1% of its assets invested UnitedHealth Group Inc.
Vanguard Health Care Fund seeks long-term growth of capital and dividend income. VGHCX invests in common stocks of companies in a variety of segments of the healthcare industry, which include pharmaceutical firms, designers and manufacturers of medical equipment and supplies, operators of hospitals and other healthcare facilities, and biotechnological researchers.
Vanguard Health Care Fund has three-year annualized returns of 6.9%. VGHCX has an expense ratio of 0.34% compared with the category average of 1.03%.
T. Rowe Price Health Sciences Fund seeks long-term capital appreciation. PRHSX invests most of its assets in common stocks of companies engaged in the research, development, production, or distribution of products or services related to healthcare, medicine, or life sciences.
T. Rowe Price Health Sciences Fund has three-year annualized returns of 6.2%. Ziad Bakri has been the fund manager of PRHSX since March 2016.
To view the Zacks Rank and the past performance of all healthcare mutual funds, investors can click here to see the complete list of healthcare mutual funds.
Want key mutual fund info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing mutual funds, each week. Get it free >>
View All Zacks #1 Ranked Mutual Funds
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Get Your Free (VGHCX): Fund Analysis Report
Get Your Free (PRHSX): Fund Analysis Report
Get Your Free (JNGLX): Fund Analysis Report
